The Company entered into two financing agreements that enables the potential access to up to $60 million of additional capital, potentially strengthening its financial position.
Entered into an At-the-Market (ATM) equity offering agreement with Canaccord Genuity LLC pursuant to which Canaccord will, at the Company?s option, use reasonable best efforts to sell up to $30 million of our common stock at our direction.
Entered into common stock purchase and registration rights agreements with Lincoln Park Capital Fund, LLC (LPC), a Chicago-based institutional investor, under which we will have the right and the sole discretion to sell to LPC up to $30 million worth of shares over a 36-month period at market rates based on closing prices in the past 10 days from when a sales of shares may occur, subject to certain limitations under the agreement as further described below under the section titled "Financing Agreement Details".
"...announced today that it has been awarded a milestone-based contract of initial value of $6 million with a potential value of up to $69 million, if all contract options are exercised, from the Biomedical Advanced Research and Development Authority (BARDA) ..."
"Management projects revenue for the full year 2020 to range from $14.0 million to $17.0 million,including product revenue between $8.0 million and $10.0 million and research and grant contribution revenue of $6.0 million to $7.0 million "
Angesichts des hohen Verlustes und des niedrigen Cashbestands bin ich eher skeptisch was die kurzfristigen Zukunftsaussichten anbetrifft. Siehe auch Posting #70